CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer

(2012) Andreas Trojan et al.   Breast Care

Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry

(2012) Takayuki Iwamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

(2012) P. D. P. Pharoah et al.   JNCI-Journal of the National Cancer Institute

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) Y. Nakamura et al.   JNCI-Journal of the National Cancer Institute

Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) V. Stanton   JNCI-Journal of the National Cancer Institute

CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

(2012) James M. Rae et al.   JNCI-Journal of the National Cancer Institute

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

(2012) Meredith M. Regan et al.   JNCI-Journal of the National Cancer Institute

Initialization of adjuvant hormonal treatment for breast cancer

(2011) Antonia Martínez Guisado et al.   ADVANCES IN THERAPY

Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials

(2011) M. P. Goetz et al.   CLINICAL CANCER RESEARCH

Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score

(2011) M F Barginear et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

(2011) L Madlensky et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment

(2011) Anne-Joy M. de Graan et al.   JOURNAL OF CLINICAL ONCOLOGY

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

(2011) William J. Irvin et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenetics of Endocrine Therapy for Breast Cancer

(2010) Michaela J. Higgins et al.   Annual Review of Medicine

Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen

(2010) Nava Siegelmann-Danieli et al.   BREAST CANCER RESEARCH AND TREATMENT

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

(2010) Alastair M. Thompson et al.   BREAST CANCER RESEARCH AND TREATMENT

Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients

(2010) Kazuma Kiyotani et al.   JOURNAL OF CLINICAL ONCOLOGY

Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients

(2010) Silvana Borges et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

(2010) Walter J. Loos et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Pharmacogenomics of Tamoxifen Therapy

(2009) H. Brauch et al.   CLINICAL CHEMISTRY

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

(2009) Werner Schroth   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Expression of ER-α36, a Novel Variant of Estrogen Receptor α, and Resistance to Tamoxifen Treatment in Breast Cancer

(2009) Liang Shi et al.   JOURNAL OF CLINICAL ONCOLOGY

Genotype-guided tamoxifen therapy: time to pause for reflection?

(2009) Timothy L Lash et al.   LANCET ONCOLOGY

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

(2009) J M Rae et al.   PHARMACOGENOMICS JOURNAL

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93

(2008) Olivia Pagani et al.   BREAST CANCER RESEARCH AND TREATMENT

Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors—International Breast Cancer Study Group

(2008) Giuseppe Viale et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

(2008) R. S. Punglia et al.   JNCI-Journal of the National Cancer Institute